Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery

Anthony S Malamas1, Maneesh Gujrati, China M Kummitha

  • 1Department of Biomedical Engineering, Case Western Reserve University, Cleveland 44106, USA.

Insights

New lipid carriers efficiently deliver small interfering RNA (siRNA) for cancer therapy by releasing it into cells. These pH-sensitive carriers show promise for gene silencing applications.

Area of Science:

  • Biotechnology
  • Nanotechnology
  • Molecular Biology

Background:

  • Synthetic small interfering RNA (siRNA) holds promise for cancer therapeutics.
  • Effective siRNA delivery into target cells and endosomal escape are critical challenges.
  • Lysosomal degradation of siRNA necessitates advanced delivery systems.

Purpose of the Study:

  • To design and optimize amphiphilic cationic lipid carriers for pH-sensitive endosomal escape.
  • To enable efficient cytosolic release of siRNA payloads.
  • To investigate structure-activity relationships for enhanced transfection and gene silencing.

Main Methods:

  • Synthesis of eight lipid carriers using solid-phase chemistry.
  • Evaluation of carrier properties: protonable amine number, pKa, hydrophobic tail unsaturation, and histidine presence.
  • In vitro screening in CHO and HT29 cells for gene knockdown (GFP, luciferase) and cytotoxicity.

Main Results:

  • At least 80% GFP knockdown in CHO cells; ECO and ECLn carriers achieved significant luciferase knockdown (22.7-23.5%) in HT29 cells, outperforming Lipofectamine RNAiMax.
  • ECO and ECLn carriers exhibited minimal cytotoxicity (87-89% cell viability).
  • Hemolysis assays indicated improved membrane disruption at pH 6.5 with increased amines and removed histidine; increased unsaturation enhanced cellular uptake.

Conclusions:

  • Optimized lipid carriers (ECO, ECLn) demonstrate efficient in vitro siRNA delivery and gene silencing in cancer cells.
  • Carrier design, including amine number and lipid tail unsaturation, influences endosomal escape and cellular uptake.
  • These pH-sensitive carriers are promising candidates for future in vivo siRNA therapeutic development.